K. Burock
Impact in
- Hepatology top 0.1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
Papers in
-
- Renal cell carcinoma treatment 8
- Lung Cancer Treatments and Mutations 2
-
- Hepatocellular Carcinoma Treatment and Prognosis 6
- Co-authors
- Ann‐Lii Cheng (6 shared papers)D. Voliotis (6 shared papers)Yoon‐Koo Kang (2 shared papers)Won Young Tak (4 shared papers)Tsai‐Sheng Yang (1 shared paper)Jiejun Wang (1 shared paper)Zhendong Chen (1 shared paper)Zhongzhen Guan (1 shared paper)
- Journals
- Journal of Clinical Oncology (6 papers)Journal of Hepatology (1 paper)The Lancet Haematology (1 paper)HemaSphere (1 paper)Annals of Oncology (1 paper)
- Partner nations
- United StatesGermanyTaiwan
In The Last Decade
K. Burock
22 papers receiving 4.8k citations
K. Burock's Hit Papers
Peers
Comparison fields: 5 of 85
- Hepatology 3.0k
- Cancer Research 764
- Pathology and Forensic Medicine 761
- Oncology 720
- Epidemiology 838
Countries citing papers authored by K. Burock
This map shows the geographic impact of K. Burock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Burock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Burock more than expected).
Fields of papers citing papers by K. Burock
This network shows the impact of papers produced by K. Burock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Burock. The network helps show where K. Burock may publish in the future.
Co-authors
The 25 scholars most cited alongside K. Burock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2008 | 4666 |
| 2 | 2011 | 107 | |
| 3 | 2007 | 29 | |
| 4 | 2020 | 22 | |
| 5 | 2008 | 17 | |
| 6 | 2012 | 16 | |
| 7 | 2017 | 12 | |
| 8 | 2006 | 10 | |
| 9 | 2009 | 9 | |
| 10 | 2009 | 8 | |
| 11 | 2024 | 5 | |
| 12 | 2008 | 4 | |
| 13 | 2009 | 2 | |
| 14 | 2009 | 2 | |
| 15 | 2009 | 2 | |
| 16 | 2009 | 2 | |
| 17 | 2023 | 1 | |
| 18 | 2009 | 1 | |
| 19 | 2009 | 1 | |
| 20 | 2025 | 1 |
About K. Burock
K. Burock is a scholar working on Pulmonary and Respiratory Medicine, Hepatology, Cancer Research, Oncology and Hematology, having authored 22 papers that have together received 4.9k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Cancer Genomics and Diagnostics (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Hematopoietic Stem Cell Transplantation (3 papers), Acute Myeloid Leukemia Research (2 papers), Economic and Financial Impacts of Cancer (2 papers) and Lung Cancer Treatments and Mutations (2 papers). The work is most often cited by research in Hepatology (3.0k citations), Cancer Research (764 citations), Pathology and Forensic Medicine (761 citations), Oncology (720 citations) and Epidemiology (838 citations). K. Burock has collaborated with scholars based in United States, Germany and Taiwan. Frequent co-authors include Ann‐Lii Cheng, D. Voliotis, Yoon‐Koo Kang, Won Young Tak, Tsai‐Sheng Yang, Jiejun Wang, Zhendong Chen, Zhongzhen Guan, Jiwei Liu and Rongcheng Luo. Their work appears in journals such as Journal of Clinical Oncology, Journal of Hepatology, The Lancet Haematology, HemaSphere and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.